Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.00 -0.15 (-0.59%)
Streaming Delayed Price Updated: 1:55 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
News headline image
1 of Wall Street’s Favorite Stock to Target This Week and 2 That Underwhelm
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Economy
News headline image
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
Via ACCESS Newswire
News headline image
2 Reasons AMPH is Risky and 1 Stock to Buy Instead
Since April 2025, Amphastar Pharmaceuticals has been in a holding pattern, floating around $24.52. The stock also fell short of the S&P 500’s 22.9% gain during that period. 
Via StockStory
Topics Economy Government Stocks
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Demystifying Amphastar Pharma: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns. 
Via Benzinga
Topics Government World Trade
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
3 Value Stocks with Warning Signs
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Value Investor's Opportunity ↗
Amphastar Pharmaceuticals appears undervalued with a low P/E ratio, strong profitability, and solid financial health, fitting value investing criteria. 
Via Chartmill
News headline image
3 Low-Volatility Stocks with Open Questions
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
3 Small-Cap Stocks That Concern Us
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Presents a Compelling Value Investment Case ↗
Amphastar Pharmaceuticals (AMPH) is a value stock with strong profitability, a low P/E ratio, and solid financial health, trading below intrinsic value. 
Via Chartmill
News headline image
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Profitable Stocks We Steer Clear Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference
Via ACCESS Newswire
News headline image
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Value Stock with Strong Fundamentals and Undervalued Potential ↗
Amphastar Pharmaceuticals (AMPH) offers strong value potential with low P/E ratios, high profitability, and stable finances, making it a solid pick for value investors seeking undervalued stocks. 
Via Chartmill
News headline image
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Lawsuit
News headline image
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum ↗
FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch. 
Via Benzinga
News headline image
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
Via ACCESS Newswire
News headline image
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
Via ACCESS Newswire
News headline image
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6%
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 4.4% year on year to $174.4 million. Its non-GAAP profit... 
Via StockStory
News headline image
Amphastar (AMPH) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Supply Chain
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
Via ACCESS Newswire
News headline image
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025
Via ACCESS Newswire
News headline image
3 Low-Volatility Stocks with Questionable Fundamentals
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Topics Supply Chain
News headline image
Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 
Via StockStory
Topics Stocks World Trade
News headline image
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>